Metuzumab
Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2].
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Caspase Isoforms
More
Biological Activity
Human
|
Caspase-3 |
Bcl-2 |
Bax |
Metuzumab (0.1-100 μg/ml; 48 h) inhibits migration of SMMC-7721 cells in 2D culture in a dose-dependent manner[1].
Metuzumab (0.1-100 μg/ml; 24 h) inhibits invasion of SMMC-7721 cells in 2D Transwell assays in a dose-dependent manner[1].
Metuzumab (0.1-100 μg/ml; 48 h) inhibits proliferation of SMMC-7721 cells in 2D, 3DP, and 3DPF models in a dose-dependent manner[1].
Metuzumab (24 h) induces G1-phase arrest in A549, NCI-H460, and NCI-H520 NSCLC cells when combined with Gemcitabine, downregulating cyclin D1[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human hepatocellular carcinoma SMMC-7721 cells (2D model)
-
Concentration:0.1-100 μg/ml
-
Incubation Time:48 h
-
Result:Decreased migration distance with increasing dose; distances for 1, 10, 100 μg/ml groups were 126.1 ± 6.7 μm, 98.8 ± 2.4 μm, 73.3 ± 8.5 μm, respectively, all significantly shorter than negative control and 0.1 μg/ml groups
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c athymic nude mice (female, 5–6 weeks old)[2]
-
Dosage:10 mg/kg
-
Administration:twice weekly
-
Result:Reduced tumor volume by 39.34% (A549), 36.39% (NCI-H460), and 35.18% (NCI-H520) compared to saline controls. Enhanced tumor growth inhibition to 91.89% (A549, p < 0.001 vs. GP alone), 73.99% (NCI-H460, p = 0.0001 vs. GP alone), and 69.74% (NCI-H520, p < 0.001 vs. GP alone) when combined with GP. Increased deoxycytidine kinase (dCK) expression by 2.1-fold (A549), 1.4-fold (NCI-H460), and 1.7-fold (NCI-H520) in tumor tissues (measured by IOD).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Synonyms
Licartin; Metuximab; Mehuzumab
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Li Y, et al. 3D bioprinting of hepatoma cells and application with microfluidics for pharmacodynamic test of Metuzumab. Biofabrication. 2019;11(3):034102. Published 2019 Jun 26. [Content Brief]
[2]. Feng F, et al. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma. Cancer Biol Ther. 2017;18(1):51-62. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Metuzumab Related Classifications
HY-P991883 Related Classifications
Powered by Bioz
- Metuzumab
- Licartin
- Metuximab
- Mehuzumab
- Apoptosis
- CDK
- Caspase
- Bcl-2 Family
- apoptosis
- Bcl-2
- full-length caspase-3
- A549
- antibody-dependent cell-mediated cytotoxicity
- non-small cell lung carcinoma
- SMMC-7721 cells
- NCI-H520
- Bax
- deoxycytidine kinase
- NSCLC xenograft models
- cisplatin
- cyclin D1
- gemcitabine
- 3D co-culture microfluidic models
- NCI-H460
- BALB/c athymic nude mice
- G1 arrest
- CD147
- PBMCs
- hepatoma cells
- Inhibitor
- inhibitor
- inhibit